Agreements

Date: 2014-06-19

Type of information: Milestone

Compound:

Company: Boehringer Ingelheim (Germany) Evotec (Germany)

Therapeutic area: CNS diseases - Inflammatory diseases - Cardiovascular diseases - Respiratory diseases - Cancer - Oncology

Type agreement: R&D - research - development

Action mechanism:

Disease:

Details:

• On November 9, 2009, Evotec announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years. The collaboration was initiated in August 2004 and has been extended on two previous occasions. At the same time, based on the success to date in the areas of CNS, inflammation, cardiometabolic and respiratory diseases the scope of the collaboration has been expanded to also include oncology targets. Over the term of the extension Evotec will receive research funding of around € 15 million plus success milestones and royalties.

Financial terms:

Latest news:

• On December 1, 2017, Evotec announced that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of € 2 million to Evotec. The milestone was for the transition of a respiratory candidate compound into a Phase I clinical trial.
• On June 19, 2014, Evotec announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of € 1.0 m to Evotec. The milestone was for the transition of a back-up compound from a respiratory programme into pre-clinical development.